Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)
Clinical trial NCT06553638 · UNKNOWN
Trial details
- NCT number
- NCT06553638
- Sponsor
- University Hospital, Brest
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2024-08-12
- Primary completion
- 2026-05-31
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.